Progress and problems for randomized clinical trials: From streptomycin to the era of megatrials

European Heart Journal

Volumn 27, Issue 18, 2006, Pages 2158-2164

  Hilbrich, Lutz ^a   Sleight, Peter ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Conflicts of interest; Ethics; Funding; Industry collaboration; Randomized clinical trials; Regulation

Indexed keywords

STREPTOMYCIN;

CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; CONTROLLED CLINICAL TRIAL; COST; DRUG INDUSTRY; EDUCATION; ETHICS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FUNDING; GOOD CLINICAL PRACTICE; GOVERNMENT; HUMAN; INFORMED CONSENT; LEGAL ASPECT; MEDICAL EXPERT; POLICY; PRIORITY JOURNAL; RANDOM ERROR; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SAFETY; SYMBIOSIS;

COMPUTER SECURITY; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, MEDICAL; HUMANS; INFORMED CONSENT; INTERPROFESSIONAL RELATIONS; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PUBLISHING; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT; RESEARCH SUPPORT AS TOPIC; SCIENTIFIC MISCONDUCT;

EID: 33748805503     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl152     Document Type: Review

References (58)

1. Pfuetze KH, Pyle MM, Hinshaw HC, Feldman WH. The first clinical trial of streptomycin in human tuberculosis. Am Rev Tuberc 1955;71:752-754.
2. Charlton BG. Megatrials are based on a methodological mistake. Br J Gen Pract 1996;46:429-431.
3. Barer D, Sacristan JA, Galende I. Clinical trials: simple megatrials are not sufficient. BMJ 1999;318:1138.
4. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stats Med 1984;3:409-422.
5. Fleming TR. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
6. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996;313:652-659.
7. Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Ann N Y Acad Sci 1978;304:267-292.
8. Peart WS, Miall WE. MRC treatment trial for mild hypertension. BMJ 1977;ii:1023.
9. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;ii:57-66.
10. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
11. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596-601.
12. Asia Pacific Consensus Forum on Stroke Management. Stroke 1998;29:1730-1736.
13. Wong E. Clinical research in China. Drug Inf J 1997;31:93-95.
14. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Lin LS; COMMIT (ClOpidogrel Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621.
15. Jayaraman KS. Outsourcing clinical trials to India rash and risky, critics warn. Nat Med 2004;10:440.
16. Yusuf S, Hawkins S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2004;364:937-952.
17. Yusuf S. Randomized clinical trials: slow death by a thousand unnecessary policies. CMAJ 2004;171:889-892.
18. Lock S. Lessons from the Pearce affair: handling scientific fraud. BMJ 1995;310:1547.
19. Burman WJ, Reves RR, Cohn DL, Schooley RT. Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med 2001;134:152-157.
20. International Conference on Harmonisation. Good clinical practice: consolidated guidelines. London, European Agency for the Evaluation of Medicinal Products; 1997.
21. Warlow C. Over-regulation of clinical research: a threat to public health. Clin Med 2005;5:33-38.
22. Glasziou P, Chalmers I. Ethics review roulette: what can we learn? BMJ 2004;328:940-943.
23. Al-Shahi R, Vousden C, Warlow C; Scottish Intracranial Vascular Malformation Study (SIVMS) Steering Committee. Bias from requiring explicit consent from all participants in observational research: prospective, population based study. BMJ 2005;331:942-947.
24. Davies J. Doctors should be allowed to offer patients a simplified form of consent, expert says. BMJ 2005;331:925.
25. Gifford F. Community-equipoise and the ethics of randomized clinical trials. Bioethics 1995;9:127-148.
26. Editorial. Trialists should tell participants results, but how? Lancet 2006;367:1030.
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
28. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
29. Fox KM. European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
30. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
31. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.
32. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
33. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-365.
34. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
35. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000;355:337-345.
36. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
37. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031.
38. MRC/BHF. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-741.
39. Collier J, Iheanacho I. The pharmaceutical industry as an informant. Lancet 2002;360:1405-1409.
40. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 2004;38:579-585.
41. De Angelis C, Drazen JM, Frizelle FA, for the International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 2004;364:911-912.
42. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van der Weyden MB, International Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 2005;365:1827-1829.
43. Public Library of Science. Announcing PLoS clinical trials. http://www.plosclinicaltrials.org (18 January 2006).
44. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-2051.
45. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S, ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-913.
46. Sleight P. Data-monitoring committees in clinical trials. Lancet 1993;341:1219-1220.
47. Messerli FH. ALLHAT, or the soft science of secondary end point. Ann Intern Med 2003;139:770-780.
48. Bodenheimer T. Uneasy alliance-clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342:1539-1544.
49. Tavazzi L. Evidence-based therapeutic strategies. There is the need to bridge the gap between simplified megatrials and individual prescriptions. Ital Heart J 2001;2:73-77.
50. Department of Health. Research Governance Framework for Health and Social Care. http//www:dh.gov.uk/PolicyAndGuidence/ResearchAnd Development (7 April 2006).
51. Medical Research Council. MRC guidelines for good clinical practice in clinical trials. London, Medical Research Council; 1998.
52. DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005;365:711-722.
53. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: part II. Circulation 2002;106:880-886.
54. Donnan GA, Davis SM, Kaste M, International Trial Subcommittee of the International Stroke Liaison Committee, American Stroke Association. Recommendations for the relationship between sponsors and investigators in the design and conduct of clinical stroke trials. Stroke 2003;34:1041-1045.
55. Iversen A, Liddel K, Fear N, Hotopf M, Wessely S. Consent confidentiality and the Data Protection Act. BMJ 2006;332:166-169.
56. Walley T. Using personal health information in medical research. BMJ 2006;332:130-131.
57. Goldblatt P. Commentary: evidence with help achieve consensus. BMJ 2006;332:169.
58. Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical research: double blind randomised trial of 'opt-in' versus 'opt-out' strategies. BMJ 2005;331:940-943.